Vimta Labs lands first biologics order, budgets ₹80 cr capex for FY27
Q1 results were already disclosed; the concall adds the domestic biologics win and a ₹80 cr capex plan, including ₹10 cr for the new unit.
— 2 earlier stories on Vimta Labs Ltd. →What's new
- First biologics services order from a domestic customer, facility now operational.
- Capex budget of ₹80 cr for FY27, with ₹10 cr earmarked for the biologics unit.
- EBITDA margin moderated sequentially due to facility costs and rupee appreciation, but management expects it to hold.
Why this matters
Biologics is a new growth vector for Vimta and the first order validates the investment. The ₹80 cr capex signals confidence in the medium-term outlook, even if Q1 margins took a temporary hit. Execution on the biologics pipeline will be the key swing factor.
What we're watching
- Size and ramp of the biologics order book over the next two quarters.
- Whether EBITDA margin can stabilize at the ~36% level seen in Q1.
- Recovery in food testing as global trade disruptions ease.
The full read
Vimta Labs' Q1 numbers were already out — revenue up 13.7% to ₹1,129 million, EBITDA at 36.4%. The concall added colour, not new math. What stood out: the first biologics services order from a domestic customer and a ₹80 crore FY27 capex plan that includes ₹10 crore for the biologics unit. Margins slipped sequentially on facility costs and rupee strength, but management expects them to hold. Food testing remains under pressure from global trade disruption, though domestic demand is cushioning the fall. Vimta is net debt-free and cautiously optimistic. The biologics order is a genuine new vector; the capex says management believes in it. Execution is all that matters from here.
Questions answered
- What is the significance of the first biologics order?
- It marks Vimta's entry into the biologics testing space with a domestic client. The facility is now operational, and this order provides initial revenue validation for a ₹10 cr capex investment made this year.
- How does the ₹80 cr capex compare with historical spending?
- The filing does not provide historical capex figures, but ₹80 cr is a notable sum against a market cap of ₹2,671 cr and trailing revenue of ~₹4,600 cr. It suggests management is investing aggressively in growth.
- Why did EBITDA margin moderate sequentially?
- Management cited facility start-up costs for the biologics unit and rupee appreciation as headwinds. They expect margins to hold at current levels as revenue scales.
- What is the outlook for the food testing business?
- Global trade disruption has pressured food testing, but domestic demand provided an offset. The segment remains a drag but is not deteriorating further.
Vimta Labs Ltd.
Latest quarter · Dec 2024
Strength & growth
Story so far
All notes on VIMTALABS →- 20 Jul 2026 · 5:06 PM IST Vimta Labs lands first biologics order, budgets ₹80 cr capex for FY27
- 2d ago Vimta Labs Q1 revenue up 13.7%, EBITDA margin at 36.4%
- 2d ago Vimta Labs Q1: Revenue up 12%, PAT up 11% — steady but not a catalyst